FDA updates its guidance, potentially enabling broader adoption of LLM-based clinical decision support software in radiology.
Key Details
- 1FDA released updated guidance on regulating clinical decision-support (CDS) software as a medical device in January 2024.
- 2The new guidance clarifies that certain LLM and CDS tools that do not directly analyze images may be exempt from device regulation if they meet four specific criteria.
- 3Previously, tools generating diagnostic text recommendations or risk predictions were typically regulated as medical devices.
- 4The updated interpretation may open opportunities for more LLM-based applications to assist radiologists without requiring full FDA device approval, provided clinicians retain review authority.
- 5Image-analyzing AI (such as CAD or denoising tools) remains regulated as medical devices.
Why It Matters
This policy shift could accelerate development and clinical adoption of text-based AI assistants and reporting tools in radiology, reducing regulatory barriers. Clarity from the FDA also helps innovators and healthcare providers assess which AI-driven software must undergo formal device review.
Source
AuntMinnie
Related News
•Radiology Business
Pennsylvania Bill Mandates AI Use Disclosure in Healthcare Facilities
Pennsylvania House passes a bill requiring healthcare facilities, including imaging centers, to disclose their use of AI in clinical care.
•Radiology Business
Radiology Societies Urge Patient Safety in FDA Generative AI Regulation
RSNA and ACR call for patient safety and ongoing monitoring as the FDA considers regulations for generative AI in radiology.
•AuntMinnie
HPI Rebuts AI's Supposed Impact on Radiology Workforce Shortage
Harvey L. Neiman HPI challenges recent claims that AI has lessened the radiology workforce burden, citing evidence of rising workloads and imaging volumes.